Bladder Cancer Surgery

(Source: BJU International)

Source: MedWorm: Bladder Cancer

Conclusion  PDD during initial TUR-BT in T1G3 bladder cancer seems to reduce significantly the rate of recurrence in our study population.
Therefore, PDD seems to be associated with superior initial tumour control and more effective tumour treatment even in patients
with highly aggressive tumours like T1G3 bladder cancer.

Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00345-010-0574-yAuthors
Peter Stanislaus, Ludwig-Maximilians-University Department of Urology LMU, Marchionistr. 15 81377 Munich GermanyDirk Zaak, Ludwig-Maximilians-University Department of Urology LMU, Marchionistr. 15 81377 Munich GermanyThomas Stadler, Ludwig-Maximilians-University Department of Urology LMU, Marchionistr. 15 81377 Munich GermanyStefan Tritschler, Ludwig-Maximilian… Source: MedWorm: Bladder Cancer

To evaluate for risk factors associated with bladder cancer recurrence in patients with pathologically negative lymph nodes.A retrospective review of 405 patients undergoing radical cystectomy for bladder cancer between 1996 and 2008 was performed. Patients with node-positive disease and (Source: Journal of Surgical Oncology) Source: MedWorm: Bladder Cancer

(Source: HemOncToday.com) Source: MedWorm: Bladder Cancer

Authors: Agrawal U, Mishra AK, Salgia P, Verma S, Mohanty NK, Saxena S
Non muscle invasive bladder cancers recur frequently and identification of biomarkers for predicting recurrence are necessary. The present study evaluated the individual and synergistic effects of tumor suppressor (p53/p21waf1) and angiogenesis [vascular endothelial growth factor (VEGF)/endoglin (CD105)] markers. The study included 90 cases of non muscle invasive bladder cancer. Cell spots were stained with primary antibodies and Flourescein isothiocyanate (FITC). Slides were observed under confocal laser scanning microscope for protein expression. The association between the markers individually and synergistically with recurrence were assessed by a chi2 and Fisher’s Exact test. Survival analysis was performed to p… Source: MedWorm: Bladder Cancer

BERKELEY, CA (UroToday.com) – Non-invasive bladder cancer is a tumor with a variable biological potential that shows a recurrence rate… (Source: UroToday) Source: MedWorm: Bladder Cancer

CONCLUSIONS First tumour recurrence appears different to subsequent recurrences; incomplete resection and tumour cell reimplantation may dominate at this time-point. Only later does genuine new tumour formation appear to increase in importance. This has important implications for clinical trials, especially those involving chemopreventive agents.
PMID: 20522307 [PubMed - as supplied by publisher] (Source: Annals of the Royal College of Surgeons of England) Source: MedWorm: Bladder Cancer

Abstract: There are few reliable markers to distinguish tumors with aggressive characteristics from others at the time of initial diagnosis in non-muscle-invasive bladder cancer. The purpose of this study was to identify a genomic marker that allows the prediction of prognosis for non-muscle-invasive bladder cancers. We screened the genome-wide copy number in 41 patients with non-muscle-invasive urothelial carcinoma of the bladder by array-based comparative genomic hybridization using arrays spotted with 4,030 bacterial artificial chromosome clones. A loss of 8p23.3 (clone 923) was correlated significantly with a higher histological grade (P = 0.0026) and advanced pathological stage (P = 0.0148). Both recurrence-free and progression-free survival rates were lower in patients with tumors wi…

Source: MedWorm: Bladder Cancer

have been treated with bcg for bladder cancer, 30 times over two years, suspect have some skin cancers and now bladder cancer has returned.

This study included 115 consecutive patients diagnosed as having NMIBC following TUR. Expression levels of E-cadherin and N-cadherin in TUR specimens from these patients were measured by immunohistochemical staining. In this series, intravesical recurrence occurred in 35 of 115 patients (30.4%). Immunohistochemical study showed that positive expression of E-cadherin and N-cadherin were noted in 62 (53.9%) and 48 (41.7%) specimens, respectively. Intravesical recurrence was detected in only 7 of 62 patients (11.3%) with positive E-cadherin expression, while 33 of 48 patients (68.8%) with positive N-cadherin expression developed intravesical recurrence. When patients were divided into 4 groups according to the positivities of E-cadherin and N-cadherin expression, intravesical recurrence was d…

Source: MedWorm: Bladder Cancer